Skip to main content

Advertisement

SpringerLink
Log in

Controversies in the Role of Radiotherapy in the Treatment of Pediatric Hodgkin Lymphoma

  • Symposium on Pediatric Oncology: Hemato-Oncology
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Hodgkin lymphoma in children is a highly curable malignancy with current approaches utilizing combined modality therapy and a risk-adapted approach. The combination of anthracyclines, bleomycin, and radiotherapy, as well as other alkylating agents, are significant risk factors for secondary malignancies and cardiopulmonary toxicity. Therefore, current strategies aim to optimize cure rates while minimizing late effects. The role of radiotherapy has been examined in recent pediatric trials, with varying results. However, they provide evidence, as a whole, for the omission of radiotherapy for a subgroup of patients, without compromising outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barbaro PM, Johnston K, Dalla-Pozza L, Cohn RJ, Wang YA, Marshall GM, et al. Reduced incidence of second solid tumors in survivors of childhood Hodgkin’s lymphoma treated without radiation therapy. Ann Oncol. 2011;22:2569–74.

    Article  PubMed  CAS  Google Scholar 

  2. O’Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin’s lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010;28:1232–9.

    Article  PubMed  Google Scholar 

  3. Omer B, Kadan-Lottick NS, Roberts KB, Wang R, Demsky C, Kupfer GM, et al. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br J Haematol. 2012;158:615–25.

    Article  PubMed  Google Scholar 

  4. Schellong G, Riepenhausen M, Bruch C, Kotthoff S, Vogt J, Bölling T, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55:1145–52.

    Article  PubMed  Google Scholar 

  5. Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study. Blood. 2011;117:1806–16.

    Article  PubMed  CAS  Google Scholar 

  6. Bhatti P, Veiga LH, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: An update from the childhood cancer survivor study. Radiat Res. 2010;174:741–52.

    Article  PubMed  CAS  Google Scholar 

  7. Demirkaya M, Sevinir B, Sağlam H, Özkan L, Akaci O. Thyroid functions in long-term survivors of pediatric Hodgkin’s lymphoma treated with chemotherapy and radiotherapy. J Clin Res Pediatr Endocrinol. 2011;3:89–94.

    Article  PubMed  Google Scholar 

  8. Schellong G, Pötter R, Brämswig J, Wagner W, Prott FJ, Dörffel W, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin’s Disease Study Group. J Clin Oncol. 1999;17:3736–44.

    PubMed  CAS  Google Scholar 

  9. Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin’s disease in children and adolescents: Analysis and outlook. Klin Padiatr. 2003;215:139–45.

    Article  PubMed  Google Scholar 

  10. Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: The GPOH-HD-2002 study. J Clin Oncol. 2010;28:3680–6.

    Article  PubMed  Google Scholar 

  11. Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG, et al. POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: A report from the Children’s Oncology Group. J Pediatr Hematol Oncol. 2006;28:362–8.

    Google Scholar 

  12. Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59:1259–65.

    Article  PubMed  Google Scholar 

  13. Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J, et al. Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin’s lymphoma–A report from the Children’s Oncology Group. J Clin Oncol. 2012;30:3174–80.

    Article  PubMed  Google Scholar 

  14. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765–71.

    Article  PubMed  Google Scholar 

  15. Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012;307:2609–16.

    Article  PubMed  CAS  Google Scholar 

  16. Friedman DL, Wolden SL, Constine L, Chen L, McCarten K, Fitzgerald TJ, et al. AHOD0031: A phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma: A report from the Children’s Oncology Group. Orlando: American Society of Hematology; 2010.

    Google Scholar 

  17. Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol. 1997;15:2769–79.

    PubMed  CAS  Google Scholar 

  18. Kelly KM, Hutchinson RJ, Sposto R, Weiner MA, Lones MA, Perkins SL, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin’s lymphoma: Preliminary results from the Children’s Cancer Group Study CCG-59704. Ann Oncol. 2002;13:S107–11.

    Article  Google Scholar 

  19. Kelly KM, Sposto R, Hutchinson R, Massey V, McCarten K, Perkins S, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: A report from the Children’s Oncology Group. Blood. 2011;117:2596–603.

    Article  PubMed  CAS  Google Scholar 

  20. Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood. 2009;114:2051–9.

    Article  PubMed  CAS  Google Scholar 

  21. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.

    Article  PubMed  CAS  Google Scholar 

  22. Appel BE, Chen L, Buxton A, Wolden SL, Hodgson DC, Nachman JB. Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59:1284–9.

    Article  PubMed  Google Scholar 

  23. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362:875–85.

    Article  PubMed  CAS  Google Scholar 

  24. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial. Blood. 2012;120:3280–7.

    Article  PubMed  CAS  Google Scholar 

  25. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, Nyengaard JR, d’Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin’s lymphoma. Haematologica. 2011;96:269–76.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

None.

Role of Funding Source

None.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Pediatrics, Children’s Hospital of Michigan, Detroit, MI, 48201, USA

    Meret Henry & Süreyya Savaşan

  2. Children’s Hospital of Michigan, Blood and Marrow Transplantation Program, Barbara Ann Karmanos Cancer Center, Wayne State University, Detroit, MI, USA

    Süreyya Savaşan

Authors
  1. Meret Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Süreyya Savaşan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meret Henry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Henry, M., Savaşan, S. Controversies in the Role of Radiotherapy in the Treatment of Pediatric Hodgkin Lymphoma. Indian J Pediatr 80, 863–869 (2013). https://doi.org/10.1007/s12098-013-1106-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-013-1106-8

Keywords

Search

Navigation